Mechanisms of vasodilation to PTH 1-84, PTH 1-34, and PTHrP 1-34 in rat bone resistance arteries.

Benson T, Menezes T, Campbell J, Bice A, Hood B, Prisby R

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA5 Jan 2016Cited by 21 (Europe PMC)

PMID26733378DOI10.1007/s00198-015-3460-zPepBankPUB-26733378

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In rat bone arteries, vasodilation was lowest with PTH 1‑34 among the three analogs.
In plain wordsIn lab tests, PTH 1‑34 produced less artery dilation than the other analogs.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVasodilation relative to other analogs
Study
ratn: not reported in source
Femoral principal nutrient arteries
Comparator
PTH 1-84 and PTHrP 1-34
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
10(-13)-10(-8) MAs given in this study (rat).
Source sentences
Summary
Vasodilation was lowest to PTH 1-34, and maximal dilation was highest to PTHrP 1-34.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
Report a problemFND-2673337801

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissueMechanism
In rat bone arteries, eNOS inhibition reduced PTH 1‑34-induced vasodilation by 66%.
In plain wordsIn lab tests, eNOS inhibition reduced artery dilation induced by PTH 1‑34.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseeNOS-dependent vasodilation
Study
ratn: not reported in source
Femoral principal nutrient arteries
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Inhibition of eNOS reduced vasodilation to PTH 1-84 (-80 %), PTH 1-34 (-66 %), and PTHrP 1-34 (-48 %), evidencing the contribution of NO.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2673337802
03LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissueMechanism
In rat bone arteries, endothelial removal impaired PTH 1‑34 vasodilation to 17% of maximum.
In plain wordsIn lab tests, removal of the artery lining reduced dilation induced by PTH 1‑34.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseEndothelium-dependent vasodilation
Study
ratn: not reported in source
Femoral principal nutrient arteries
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Vasodilation following denudation was eliminated (PTH 1-84 and PTHrP 1-34) and impaired (PTH 1-34, 17 % of maximum), highlighting the importance of endothelial cells for PTH signaling.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2673337803
04LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissueMechanism
In rat bone arteries, PKA inhibition diminished vasodilation induced by PTH 1‑34 and the other analogs.
In plain wordsIn lab tests, PKA inhibition reduced artery dilation induced by PTH 1‑34 and the other analogs.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePKA-dependent vasodilation
Study
ratn: not reported in source
Femoral principal nutrient arteries
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Both PKA and PKC inhibition diminished vasodilation in all three analogs to varying degrees.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2673337804
05LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissueMechanism
In rat bone arteries, PKC inhibition diminished vasodilation induced by PTH 1‑34 and the other analogs.
In plain wordsIn lab tests, PKC inhibition reduced artery dilation induced by PTH 1‑34 and the other analogs.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePKC-dependent vasodilation
Study
ratn: not reported in source
Femoral principal nutrient arteries
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Both PKA and PKC inhibition diminished vasodilation in all three analogs to varying degrees.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2673337805
06LabNot a test of Teriparatide (PTH 1-34) aloneEx vivo tissueMechanism
In rat bone arteries, PTH1R blockade reduced PTH 1‑34-induced vasodilation to 12%.
In plain wordsIn lab tests, receptor blockade reduced artery dilation induced by PTH 1‑34.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePTH1R-dependent vasodilation
Study
ratn: not reported in source
Femoral principal nutrient arteries
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
PTH1R blockade reduced vasodilation to 1, 12, and 12 % to PTH 1-84, PTH 1-34, and PTHrP 1-34, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Femoral principal nutrient arteries (PNAs) were given cumulative doses (10(-13)-10(-8) M) of PTH 1-84, PTH 1-34, and PTHrP 1-34 with and without signaling pathway blockade.
Summary · context
Vasodilation was also determined following endothelial cell removal (i.e., denudation), PTH 1 receptor (PTH1R) inhibition and to sodium nitroprusside (SNP; a nitric oxide [NO] donor).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2673337806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.